JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
US4323581A
(en)
|
1978-07-31 |
1982-04-06 |
Johnson & Johnson |
Method of treating carcinogenesis
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
EP0303697B1
(en)
|
1987-03-09 |
1997-10-01 |
Kyowa Hakko Kogyo Co., Ltd. |
Derivatives of physiologically active substance k-252
|
US4904768A
(en)
|
1987-08-04 |
1990-02-27 |
Bristol-Myers Company |
Epipodophyllotoxin glucoside 4'-phosphate derivatives
|
EP0383919A4
(en)
|
1988-02-04 |
1992-08-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Staurosporin derivatives
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
WO1993007153A1
(en)
|
1991-10-10 |
1993-04-15 |
Schering Corporation |
4'-(n-substituted-n-oxide)staurosporine derivatives
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
AU3064992A
(en)
|
1991-11-08 |
1993-06-07 |
University Of Southern California |
Compositions containing k-252 compounds for potentiation of neurotrophin activity
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5948898A
(en)
|
1992-03-16 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
|
US5621100A
(en)
|
1992-07-24 |
1997-04-15 |
Cephalon, Inc. |
K-252a derivatives for treatment of neurological disorders
|
US5756494A
(en)
|
1992-07-24 |
1998-05-26 |
Cephalon, Inc. |
Protein kinase inhibitors for treatment of neurological disorders
|
JP3608788B2
(ja)
|
1992-08-31 |
2005-01-12 |
ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ |
Mage−3遺伝子から誘導されてhla−a1により提示される単離されたノナペプチドおよびそれらの用途
|
CA2123895A1
(en)
|
1992-09-21 |
1994-03-31 |
Tatsuya Tamaoki |
A therapeutic agent for thrombocytopenia
|
ES2278663T3
(es)
|
1992-10-28 |
2007-08-16 |
Genentech, Inc. |
Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf.
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
KR100341341B1
(ko)
|
1993-07-15 |
2002-11-25 |
미네소타 마이닝 앤드 매뉴팩춰링 캄파니 |
이미다조[4,5-c]피리딘-4-아민
|
US5478932A
(en)
|
1993-12-02 |
1995-12-26 |
The Board Of Trustees Of The University Of Illinois |
Ecteinascidins
|
AU1339895A
(en)
|
1993-12-23 |
1995-07-10 |
Eli Lilly And Company |
Protein kinase c inhibitors
|
US5587459A
(en)
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US6083903A
(en)
|
1994-10-28 |
2000-07-04 |
Leukosite, Inc. |
Boronic ester and acid compounds, synthesis and uses
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
ES2332984T3
(es)
|
1995-03-30 |
2010-02-16 |
Pfizer Products Inc. |
Derivados de quinazolinas.
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
AU6888196A
(en)
|
1995-08-11 |
1997-03-12 |
Yale University |
Glycosylated indolocarbazole synthesis
|
FR2741881B1
(fr)
|
1995-12-01 |
1999-07-30 |
Centre Nat Rech Scient |
Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
|
IL123568A
(en)
|
1995-12-08 |
2001-08-08 |
Janssen Pharmaceutica Nv |
History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
|
KR100447918B1
(ko)
|
1996-07-25 |
2005-09-28 |
동아제약주식회사 |
대장을포함한위장관보호작용을갖는플라본및플라바논화합물
|
AU738592C
(en)
|
1996-08-02 |
2002-07-25 |
Lorus Therapeutics Inc. |
Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6126965A
(en)
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
EP1017394B1
(en)
|
1997-07-12 |
2005-12-07 |
Cancer Research Technology Limited |
Cyclin dependent kinase inhibiting purine derivatives
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
US20030083242A1
(en)
|
1998-11-06 |
2003-05-01 |
Alphonse Galdes |
Methods and compositions for treating or preventing peripheral neuropathies
|
KR100797308B1
(ko)
|
1999-06-25 |
2008-01-23 |
제넨테크, 인크. |
인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법
|
WO2001004125A1
(fr)
|
1999-07-13 |
2001-01-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives de staurosporine
|
SK287401B6
(sk)
|
1999-11-05 |
2010-09-07 |
Astrazeneca Ab |
Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
|
ES2531547T3
(es)
|
1999-12-06 |
2015-03-17 |
Geistlich Pharma Ag |
Uso de taurolidina o el taurultamo para la fabricación de un medicamento para el tratamiento de tumores
|
NZ520640A
(en)
|
2000-02-15 |
2005-04-29 |
Upjohn Co |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
AU2001253427B2
(en)
|
2000-04-12 |
2007-02-08 |
Genaera Corporation |
A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
|
CZ299561B6
(cs)
|
2000-06-30 |
2008-09-03 |
Glaxo Group Limited |
Chinazolinaminový derivát a farmaceutický prostredek
|
DK1650203T3
(da)
|
2000-09-11 |
2008-06-02 |
Novartis Vaccines & Diagnostic |
Quinolinonderivater som tyrosinkinaseinhibitorer
|
US6677450B2
(en)
|
2000-10-06 |
2004-01-13 |
Bristol-Myers Squibb Company |
Topoisomerase inhibitors
|
ATE325865T1
(de)
|
2001-01-16 |
2006-06-15 |
Regeneron Pharma |
Isolierung von sezernierte proteine exprimierenden zellen
|
WO2002062826A1
(fr)
|
2001-02-07 |
2002-08-15 |
Vadim Viktorovich Novikov |
Procede de fabrication des peptides
|
WO2003004505A1
(en)
|
2001-07-02 |
2003-01-16 |
Debiopharm S.A. |
Oxaliplatin active substance with a very low content of oxalic acid
|
KR100484504B1
(ko)
|
2001-09-18 |
2005-04-20 |
학교법인 포항공과대학교 |
쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
|
US20030134846A1
(en)
|
2001-10-09 |
2003-07-17 |
Schering Corporation |
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
|
US6927036B2
(en)
|
2002-02-19 |
2005-08-09 |
Xero Port, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
CA2480638C
(en)
|
2002-03-29 |
2013-02-12 |
Chiron Corporation |
Substituted benzazoles and use thereof as raf kinase inhibitors
|
US6727272B1
(en)
|
2002-07-15 |
2004-04-27 |
Unitech Pharmaceuticals, Inc. |
Leflunomide analogs for treating rheumatoid arthritis
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
EP1587473A4
(en)
|
2002-12-27 |
2008-08-13 |
Novartis Vaccines & Diagnostic |
THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
|
ES2391770T3
(es)
|
2003-01-21 |
2012-11-29 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos de triptantrina para la potenciación inmune
|
ES2423800T3
(es)
|
2003-03-28 |
2013-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Uso de compuestos orgánicos para la inmunopotenciación
|
MX2007009960A
(es)
*
|
2005-02-18 |
2008-03-11 |
Abraxis Bioscience Inc |
Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
JP2013542228A
(ja)
*
|
2010-11-08 |
2013-11-21 |
ノバルティス アーゲー |
Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用
|
KR20140033432A
(ko)
*
|
2011-06-21 |
2014-03-18 |
노파르티스 아게 |
(s)-피롤리딘-1,2-디카르복실산 2-아미드 1-({4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일}-아미드)의 다형체
|
EP2601965A1
(en)
*
|
2011-12-06 |
2013-06-12 |
Apeiron Biologics AG |
Compositions for preventing or treating adverse reactions of EGFR inhibition
|
US10213432B2
(en)
|
2012-05-16 |
2019-02-26 |
Novartis Ag |
Dosage regimen for a PI-3 kinase inhibitor
|